Last reviewed · How we verify
CellREADY® drug product IV dose of 50 millions
CellREADY® drug product IV dose of 50 millions is a Small molecule drug developed by University Hospital, Toulouse. It is currently in Phase 1 development.
At a glance
| Generic name | CellREADY® drug product IV dose of 50 millions |
|---|---|
| Sponsor | University Hospital, Toulouse |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CellREADY® drug product IV dose of 50 millions CI brief — competitive landscape report
- CellREADY® drug product IV dose of 50 millions updates RSS · CI watch RSS
- University Hospital, Toulouse portfolio CI
Frequently asked questions about CellREADY® drug product IV dose of 50 millions
What is CellREADY® drug product IV dose of 50 millions?
CellREADY® drug product IV dose of 50 millions is a Small molecule drug developed by University Hospital, Toulouse.
Who makes CellREADY® drug product IV dose of 50 millions?
CellREADY® drug product IV dose of 50 millions is developed by University Hospital, Toulouse (see full University Hospital, Toulouse pipeline at /company/university-hospital-toulouse).
What development phase is CellREADY® drug product IV dose of 50 millions in?
CellREADY® drug product IV dose of 50 millions is in Phase 1.